News

7/18/25

Pharmaceutical Executive

A Potential Universal Target for Autoimmune: Q&A with Richard Freed

Read More >

5/29/25

Precision Medicine Online

RheumaGen Betting on HLA Gene Editing to Tackle Autoimmune Disorders

Read More >

5/21/25

BIO

RheumaGen CEO Richard Freed to speak on autoimmune disease and cell therapy panel at the BIO International Convention on June 17, 2025 in Boston, MA

Read More >

5/14/25

Drug Discovery News

Gene-edited stem cells aim to reverse rheumatoid arthritis

Read More >

4/10/25

University of Colorado Anschutz Medical Campus

Innovation to Medication: The Path to Potential Cures for Autoimmune Diseases

Read More >

4/1/25

Inside Precision Medicine

Tackling Autoimmune Disease with Cell and Gene Therapy

Read More >

2/7/25

Medscape

RheumaGen CSO and Lead Inventor Brian Freed, Ph.D., Interviewed for Medscape Article, “Could Gene Therapy for RA Soon Be Ready to ‘Take Off?'”

Read More >

2/5/25

RheumaGen and the University of Colorado Anschutz Medical Campus Co-host Dr. Georg Schett, a World-Renowned Member of the Company’s Scientific Advisory Board, for his Ground Rounds Lecture, “CAR-T Cell Therapy in Autoimmune Diseases”

Read More >

2/3/25

RheumaGen Hosts Roundtable Discussion and Tour with Congresswoman Diana DeGette; John Crowley, President & CEO of BIO; Vineet Chopra, M.D., Chairman of the Department of Medicine, University of Colorado School of Medicine; and Elyse Blazevich, CEO of the Colorado Biosciences Association

Read More >

1/9/25

RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases

Read More >

5/23/24

BIOLIFE SUMMITS

RheumaGen CEO Richard Freed to Speak at Mountain West BioLife Summit

Read More >

5/14/24

FITZSIMONS INNOVATION COMMUNITY

RheumaGen Featured in Fitzsimons Innovation Community “Innovation Spotlight”

Read More >

5/2/24

TIME

RheumaGen’s Scientific Advisory Board Member, Georg Schett, a World-Renowned Expert in CAR T and Autoimmune Disease, Featured in Time Magazine’s Time100 Health List

Read More >

4/23/24

COLORADO BIOSCIENCE ASSOCIATION

RheumaGen CEO Richard Freed Presented at 2024 CBSA Biotech Symposium

Read More >

11/16/23

RheumaGen Awarded Grant from Colorado Office of Economic Development

Read More >

10/2/23

RheumaGen Named Colorado’s Most Innovative Emerging Company of 2023

Read More >

8/2/23

RheumaGen’s Innovative Approach to Rheumatoid Arthritis Treatment Featured on CBS News

Read More >

3/10/23

RheumaGen to present at 2023 BIO International Convention

Read More >

4/20/22

Developing cancer treatments in space

Read More >

1/19/22

QIAGEN supports young biotechnology and pharma companies by announcing winners of first-ever annual Biotech Grants

Read More >

Contact Us

Media inquiries: RheumaGen@argotpartners.com

Please be aware of scams that impersonate RheumaGen recruiters. All official communications from RheumaGen will come from a rheumagen.com email address, and we will never ask for sensitive personal or financial information from candidates.

Dedicated to Patients in Need

RheumaGen was founded to relieve the burden that individuals suffering from autoimmune diseases have carried for so long. Mindful also of our own family members who are patients, we are not interested in incremental improvements. We seek cures; we seek remission.

Learn Our Story